Trial Profile
A Phase 1a/1b Multicenter, Open Label, Dose-Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CWP232291 Administered Intravenously Either Alone or in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Myeloma (MM)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs CWP 291 (Primary) ; Dexamethasone; Lenalidomide
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors JW Pharmaceutical
- 15 May 2019 Status changed from recruiting to completed.
- 16 Mar 2018 Planned primary completion date changed from 1 Jul 2017 to 1 Sep 2019.
- 12 Dec 2017 Interim results (data cut off: 25 Jul, 2017; n=21) presented at the 59th Annual Meeting and Exposition of the American Society of Hematology